000 01360 a2200397 4500
005 20250518041752.0
008 ####s 0 0 eng d
022 _a1532-1827
024 7 _a10.1038/s41416-019-0487-5
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSerrano, César
245 0 0 _aCorrection: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
_h[electronic resource]
260 _bBritish journal of cancer
_cJul 2019
300 _a281 p.
_bdigital
500 _aPublication Type: Published Erratum
700 1 _aMariño-Enríquez, Adrián
700 1 _aTao, Derrick L
700 1 _aKetzer, Julia
700 1 _aEilers, Grant
700 1 _aZhu, Meijun
700 1 _aYu, Channing
700 1 _aMannan, Aristotle M
700 1 _aRubin, Brian P
700 1 _aDemetri, George D
700 1 _aRaut, Chandrajit P
700 1 _aPresnell, Ajia
700 1 _aMcKinley, Arin
700 1 _aHeinrich, Michael C
700 1 _aCzaplinski, Jeffrey T
700 1 _aSicinska, Ewa
700 1 _aBauer, Sebastian
700 1 _aGeorge, Suzanne
700 1 _aFletcher, Jonathan A
773 0 _tBritish journal of cancer
_gvol. 121
_gno. 3
_gp. 281
856 4 0 _uhttps://doi.org/10.1038/s41416-019-0487-5
_zAvailable from publisher's website
999 _c29724209
_d29724209